The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO).
 
Manish R. Patel
Leadership - ION Pharma
Honoraria - Adaptive Biotechnologies; Bayer; Genentech; Janssen Oncology; Pfizer; Pharmacyclics
Consulting or Advisory Role - Pfizer/EMD Serono; Pharmacyclics/Janssen
Speakers' Bureau - Celgene; Exelixis; Genentech/Roche; Taiho Pharmaceutical
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); Artios (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); BioTheryX (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); CicloMed (Inst); Clovis Oncology (Inst); Curis (Inst); cyteir (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Erasca, Inc (Inst); Evelo Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); IgM Biosciences (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Kymab (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); nurix (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Placon (Inst); Portola Pharmaceuticals (Inst); Prelude Therapeutics (Inst); PubGene (Inst); PureTech (Inst); PureTech (Inst); Puretech (Inst); QiLu Pharmaceutical (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Samumed (Inst); Seven and Eight Biopharmaceuticals (Inst); Silicon Therapeutics (Inst); Stemline Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TeneoBio (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Treadwell Therapeutics (Inst); Treadwell Therapeutics (Inst); Vedanta Biosciences (Inst); Verastem (Inst); Vigeo Therapeutics (Inst); Xencor (Inst); Zymeworks (Inst)
 
Vicky Makker
Consulting or Advisory Role - ArQule; Clovis Oncology; DualityBio; Eisai; Faeth Therapeutics; GlaxoSmithKline; IBM; ITeos Therapeutics; Kartos Therapeutics; Karyopharm Therapeutics; Lilly; Merck; Novartis; Takeda
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); DualityBio (Inst); Eisai (Inst); Faeth Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Eisai; Karyopharm Therapeutics; Merck
Other Relationship - IBM
 
Ana Oaknin
Consulting or Advisory Role - AGENUS; Amgen; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Deciphera; Eisai; EMD Serono; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Medison; Merck Sharp & Dohme; Mersana; Novocure; PharmaMar; prIME Oncology; Roche; Roche; Shattuck Labs; Sutro Biopharma; Tesaro
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Aprea Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Belgian Gynaecological Oncology Group (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Eisai (Inst); Immunogen (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Medimmune (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Mundipharma Research (Inst); Novartis Farmacéutica (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Sutro Biopharma (Inst); Tesaro (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche
 
Sandro Pignata
Honoraria - AstraZeneca; MSD; pfizer; pharmamar; Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Pfizer; PharmaMar; Roche; tesaro
Research Funding - AstraZeneca (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
Floor Jenniskens Backes
Consulting or Advisory Role - Abbott Diagnostics (I); Agenus; AstraZeneca; CMR Institute; Eisai; GlaxoSmithKline; Merck
Research Funding - Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate (for writing a chapter)
 
Antonio Gonzalez Martin
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; Genmab; Immunogen; Macrogenics; Mersana; MSD; Oncoinvent; Pfizer/EMD Serono; Roche; SOTIO; Sutro Biopharma; Tesaro/GSK
Speakers' Bureau - AstraZeneca; PharmaMar; Roche; Tesaro/GSK
Research Funding - Roche (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche; Tesaro/GSK
 
Ramez Nassef Eskander
Consulting or Advisory Role - Agenus; AstraZeneca/MedImmune; Clovis Oncology; Daiichi Sankyo/Lilly; Eisai; Merck; Myriad Genetics; Pfizer; Tesaro
Speakers' Bureau - AstraZeneca/MedImmune; Myriad Genetics
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Eisai; Merck
 
Bhavana Pothuri
Consulting or Advisory Role - AstraZeneca; BioAscent; Clovis Oncology; Curio Science; Department of Defense; Eisai; Elevar Therapeutics; GlaxoSmithKline; Intuitive Surgical; McGivney Global Advisors; Merck; Mersana; Rubin, Paterniti, Gonzalez LLC; Tesaro; Toray Industries; Vaniam Group
Research Funding - AstraZeneca (Inst); Celgene (Inst); Celsion (Inst); Clovis Oncology (Inst); Genentech (Inst); Immunogen (Inst); Merck (Inst); Takeda (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; Eisai; Tesaro
 
Debra L. Richardson
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; GlaxoSmithKline; Mersana
Research Funding - Aravive (Inst); ArQule (Inst); AstraZeneca (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Genentech (Inst); Harpoon therapeutics (Inst); Hookipa Biotech (Inst); Innovent Biologics (Inst); Karyopharm Therapeutics (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Roche (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
 
Angeles Alvarez Secord
Honoraria - Myriad Genetics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immutep (Inst); Merck (Inst); OncoQuest Pharmaceuticals (Inst); PharmaMar (Inst); Seagen (Inst); Tesaro (Inst); VBL Therapeutics (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Aravive; GOG Foundation; OncoQuest Pharmaceuticals; Regeneron; Roche/Genentech; VBL Therapeutics
 
Els Van Nieuwenhuysen
No Relationships to Disclose
 
Joyce F. Liu
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; Genentech/Roche; GlaxoSmithKline; Regeneron
Research Funding - 2X Oncology (Inst); Acetylon Pharmaceuticals (Inst); Agenus (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); Regeneron (Inst); Surface Oncology (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst); Zentalis (Inst)
(OPTIONAL) Uncompensated Relationships - Merck
 
Fernanda Musa
Stock and Other Ownership Interests - Clovis Oncology
Honoraria - Cooper Surgical
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Seagen
Research Funding - AGENUS (Inst); Akeso Biopharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst)
 
Richard T. Penson
Honoraria - Abbvie; AstraZeneca; Clovis Oncology; Eisai; Genentech/Roche; Janssen Oncology; Mersana; Newlink Genetics; Sutro Biopharma; Tesaro; Vascular Biogenics
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Baxalta; Care4ward; Clovis Oncology; Eisai; Genentech; Janssen Oncology; Merck; Mersana; Sutro Biopharma; Tesaro; Vascular Biogenics
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Cerulean Pharma (Inst); Eisai (Inst); Genentech (Inst); Regeneron (Inst); Sanofi (Inst); Tesaro (Inst); Vascular Biogenics (Inst)
Patents, Royalties, Other Intellectual Property - Blackwell Publishing; BMJ; UpToDate
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; Genentech; Tesaro; Vascular Biogenics
Other Relationship - Abbvie; AstraZeneca
 
Kenton Wride
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
Travel, Accommodations, Expenses - Clovis Oncology
 
Denise M. Lepley
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Rachel Dusek
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
Research Funding - Clovis Oncology
Patents, Royalties, Other Intellectual Property - Patent application related to cancer therapy involving the combination of an immunostimulatory agent with an antiangiogenic agent filed in April 2020; Patent application relating to antibodies targeting CRTAM filed Nov 2018, published August 2020
 
Teresa Cameron
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
Patents, Royalties, Other Intellectual Property - Patent application submitted January 2020 for dosing methodology (Inst)
 
Erika P. Hamilton
Consulting or Advisory Role - Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Relay Therapeutics (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Ellipses Pharma (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); InventisBio (Inst); Jacobio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Myriad Genetics (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Radius Health (Inst); Regeneron (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Nicole Concin
Honoraria - GlaxoSmithKline; Mersana
Consulting or Advisory Role - Akeso Biopharma; AstraZeneca; Eisai; eTheRNA Immunotherapies; GlaxoSmithKline; Mersana; Seagen; Seagen
Travel, Accommodations, Expenses - Amgen; Genmab; Roche Belgium